Abstract
Background: We have previously shown that a new measles, mumps, rubella (MMR) vaccine, Priorix™, with a novel mumps component elicits anti-mumps antibody titers comparable to the licensed M-M-R™II vaccine.
Materials and Methods: To ensure that these antibodies had neutralizing activity against wild-type mumps virus, sera were prepared 2 and 18 months after vaccination of 12–24-months-old infants with either Priorix™ or M-M-R™II and ELISA antibody titers and neutralizing activity were determined.
Results: After 2 months, Priorix™ and M-M-R™II vaccines elicited comparable ELISA antibody titers and neutralizing activity. At 18 months ELISA seropositivity rates were 80–81% and 94–96% of vaccinees had neutralizing activity. All ELISA seropositives had neutralizing activity.
Conclusion: These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: April 28, 2000 · Revision accepted: February 16, 2001
Rights and permissions
About this article
Cite this article
Usonis, V., Bakasenas, V. & Denis, M. Neutralization Activity and Persistence of Antibodies Induced in Response to Vaccination with a Novel Mumps Strain, RIT 4385. Infection 29, 159–162 (2001). https://doi.org/10.1007/s15010-001-1098-7
Issue Date:
DOI: https://doi.org/10.1007/s15010-001-1098-7